Cellebrite DI (NASDAQ:CLBT – Get Free Report) released its quarterly earnings data on Thursday. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03), Zacks reports. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. Cellebrite DI updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.
Cellebrite DI Stock Down 5.5 %
Shares of NASDAQ:CLBT opened at $20.50 on Friday. The company has a 50-day simple moving average of $22.58 and a 200-day simple moving average of $19.10. Cellebrite DI has a one year low of $9.96 and a one year high of $26.30.
Analyst Ratings Changes
Several equities research analysts have recently issued reports on CLBT shares. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price objective on shares of Cellebrite DI in a research report on Friday. Lake Street Capital boosted their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a research report on Friday. JPMorgan Chase & Co. boosted their price target on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, Craig Hallum boosted their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cellebrite DI currently has a consensus rating of “Buy” and an average price target of $23.43.
Cellebrite DI Company Profile
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
See Also
- Five stocks we like better than Cellebrite DI
- Market Cap Calculator: How to Calculate Market Cap
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- Health Care Stocks Explained: Why You Might Want to Invest
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.